Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VaxartSTU:NB11 50 PB Ratio is 1.78 as of Jul. 30, 2026, which is 4% below its 10-year median of 1.85. GuruFocus rates STU:NB11 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 1,228 Biotechnology companies, Vaxart ranks better than 75% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-30), Vaxart's share price is €0.60. Vaxart's Book Value per Share for the quarter that ended in Mar. 2026 was €0.34. Hence, Vaxart's PB Ratio of today is 1.78.
The historical rank and industry rank for Vaxart's PB Ratio or its related term are showing as below:
STU:NB11'
s PB Ratio Range Over the Past 10 Years
Min: 0.31 Med: 1.85 Max: 37.68
Current: 1.24
During the past 13 years, Vaxart's highest PB Ratio was 37.68. The lowest was 0.31. And the median was 1.85.
STU:NB11's PB Ratio is ranked better than 75% of 1228
companies
in the Biotechnology industry
Industry Median: 2.69
vs STU:NB11: 1.24
During the past 12 months, Vaxart's average Book Value Per Share Growth Rate was 95.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -23.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -28.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -32.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vaxart was 46.60% per year. The lowest was -72.70% per year. And the median was -6.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vaxart PB Ratio Related Terms
Vaxart PB Ratio Historical Data
* Premium members only.
The historical data trend for Vaxart's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vaxart's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaxart PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaxart's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vaxart's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vaxart's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vaxart (STU:NB11) has a PB Ratio of 1.78 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vaxart and its competitors. This is near median its historical median of 1.85. Over the past decade, Vaxart's PB Ratio has ranged from 0.31 to 37.68. According to the industry distribution chart, Vaxart ranks #307 out of 1228 companies in the Biotechnology industry, placing it in the top 25%.
Is Vaxart's PB Ratio too high?
Vaxart's current PB Ratio of 1.78 is near median its 10-year median of 1.85. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 37.68. The Biotechnology industry median PB Ratio is 2.69. Vaxart's value of 1.78 is 33.8% below this industry median. Based on the distribution chart, Vaxart ranks #307 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vaxart has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's PB Ratio compare to VTVT and SPRB?
According to the Biotechnology industry distribution chart, Vaxart ranks #307 out of 1228 companies for PB Ratio. This places Vaxart in the top 25% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.69. Vaxart's value of 1.78 is 33.8% below this benchmark. Historically, Vaxart's own PB Ratio has ranged from 0.31 to 37.68 over the past decade. While the company's 10-year median is 1.85 vs. the industry median of 2.69, Vaxart has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.69, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxart's current PB Ratio of 1.78 is 33.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vaxart and its competitors. For the Biotechnology industry, the median PB Ratio is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxart's current PB Ratio is 1.78, which is near median its own 10-year median of 1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (STU:NB11) has a current PB Ratio of 1.78. The current PB Ratio is 1.78, which is near median its 10-year median of 1.85 and 33.8% below the Biotechnology industry median of 2.69. Vaxart's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vaxart (STU:NB11), the current PB Ratio is 1.78 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
50GF Score
Get the complete analysis for STU:NB11
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NB11 has been successfully added to your 
